Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts' consensus: Six analysts cover Unicycive Therapeutics with an average recommendation of "Moderate Buy" (five buys, one sell) and an average 12‑month target of $24.75, though coverage is mixed with downgrades and target cuts (e.g., Benchmark cut its target to $15; Wall Street Zen and Weiss issued sell ratings, while B. Riley and Westpark initiated buys).
• Recent trading and financials: UNCY is trading near $7.98 with a $213M market cap, a 12‑month range of $3.71–$11.00, and reported a quarterly loss of $0.82 per share (missing estimates of $0.46), while institutional ownership is about 40% with recent stake increases by firms like State Street, JPMorgan and Citadel.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.75.

Several research analysts have issued reports on the stock. Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Westpark Capital assumed coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They set a "buy" rating on the stock. B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a report on Friday. They set a "buy" rating and a $22.00 target price on the stock. Finally, Benchmark dropped their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating on the stock in a report on Monday, April 6th.

Unicycive Therapeutics Trading Up 4.0%

NASDAQ UNCY opened at $7.98 on Tuesday. The company's 50-day moving average price is $6.88 and its 200-day moving average price is $6.20. The stock has a market cap of $213.07 million, a PE ratio of -3.68 and a beta of 1.78. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.36). As a group, sell-side analysts forecast that Unicycive Therapeutics will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its holdings in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after acquiring an additional 10,400 shares in the last quarter. Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the 2nd quarter worth about $55,000. JPMorgan Chase & Co. grew its holdings in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after acquiring an additional 21,525 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of Unicycive Therapeutics in the 4th quarter valued at about $226,000. Finally, Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at about $182,000. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.